Chesnara Plc: Acquisitions show immediate benefits
2 September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a cutting-edge biopharmaceutical company focused on developing innovative peptide therapeutics, has been gaining significant attention from investors. With a market capitalization of $3.39 billion, the..
Alphatec Holdings, Inc. (NYSE: ATEC), a prominent player in the healthcare sector specializing in medical devices, has emerged as a company of interest for investors seeking growth opportunities in the..
Sotera Health Company (NASDAQ: SHC), a prominent player in the healthcare sector’s diagnostics and research industry, presents a compelling case for investors seeking growth potential amidst market volatility. With a..
In the ever-evolving landscape of the healthcare sector, HUTCHMED (China) Limited (HCM) stands out with its significant potential upside of 52.88%, as suggested by analyst ratings. This Hong Kong-based specialty..
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) stands as a compelling investment opportunity in the biotechnology sector, with a market capitalization of $2.22 billion. The company, based in Jupiter, Florida, is a..
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a force to be reckoned with in the biotechnology sector, commanding a market capitalization of $4.11 billion. As a company dedicated to developing treatments..
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a notable player in the biotechnology industry, has been capturing investor attention with its promising pipeline and impressive potential upside. With a market capitalization..
Vericel Corporation (NASDAQ: VCEL), a prominent player in the biotechnology sector, is capturing investor attention due to its promising growth potential. With a market capitalization of $2.09 billion, Vericel is..
Investors with an eye on the healthcare sector might find Surgery Partners, Inc. (NASDAQ: SGRY) an intriguing opportunity, especially considering its potential upside of 35.36% based on current analyst targets...
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), a dynamic player in the healthcare sector with a focus on biotechnology, continues to capture investor interest with its innovative approach to treating rare..
Merus N.V. (NASDAQ: MRUS), a clinical-stage biotechnology firm based in the Netherlands, is garnering significant attention in the investor community. With a promising pipeline of innovative bispecific antibody therapeutics targeting..
Investors looking for opportunities in the healthcare sector should take a closer look at Acadia Healthcare Company, Inc. (NASDAQ: ACHC). With a market cap of $1.95 billion, this company specializes..
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a dynamic player in the biotechnology sector, has been making waves with its innovative approach to treating rare and orphan diseases. Headquartered in Foster City,..
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a prominent player in the biopharmaceutical industry, has carved a niche with its focus on developing and commercializing medicines targeting central nervous system (CNS) disorders..
CRISPR Therapeutics AG (NASDAQ: CRSP) stands at the forefront of biotechnology innovation, carving a niche in the dynamic sector with its revolutionary CRISPR/Cas9 gene-editing platform. With a current market cap..
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) stands as a noteworthy player in the biotechnology sector, with a market capitalization of $3.53 billion. This commercial-stage biopharmaceutical company is headquartered in Stamford, Connecticut,..
Privia Health Group, Inc. (NASDAQ: PRVA), a prominent player in the healthcare sector with a focus on health information services, presents an enticing opportunity for investors. With a market capitalization..
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) presents a compelling opportunity for investors looking to tap into the burgeoning biotechnology sector, particularly in the niche field of rare and ultra-rare genetic diseases...
Immunovant, Inc. (NASDAQ: IMVT) is capturing investor attention with its compelling potential upside of 180.08%, according to recent analyst ratings. As a clinical-stage biotechnology company, Immunovant is focused on developing..
Arcellx, Inc. (NASDAQ: ACLX), a promising player in the biotechnology sector, is drawing significant attention from investors with its impressive potential for growth and innovation in the field of immunotherapies...
